Global Economy
The global economy remained stable in 2025 by navigating
changing trade policies and different regional outcomes.
Technology investments in areas such as artificial intelligence
helped balance the effects of tariffs and policy changes.
Global inflation reached a steady 4.1% as several countries
reported lower figures than expected. This environment
provided global operations and research teams with a more
predictable cost structure.
World GDP growth reached 3.4% for the year with varying
results across different areas. Advanced economies grew
by 1.9% while the United States saw a 2.1% increase from
technology spending and financial support. The euro
area grew by 1.4% and Japan by 1.2%. Emerging markets
performed better with 4.4% growth where India reached
7.6% and China saw 5.0% expansion. These high performing
markets remain essential for global reach and patient access.
Trade tensions decreased after a truce between the United
States and China lowered tariffs and paused export limits on
electronic components and minerals. The United States also
removed certain agricultural tariffs which kept overall rates
similar to previous levels. While policy concerns were lower
than the peaks seen in late 2025, they remained higher than
the year before.
Financial conditions were generally helpful despite some
market changes, and high growth technology stocks
performed better than the wider market. Global trade volumes
stayed consistent because of strong technology exports from
Asia. Central banks managed inflation through small policy
changes including rate drops in the United States and the
United Kingdom. These actions helped maintain a stable
financial environment against trade and political challenges.
Outlook
The mid-term global economic outlook suggests a period
of sustained growth with projections of 3.3% for 2026 and
3.2% for 2027. This positive trend is driven by a shift toward
technology-led productivity, particularly the use of artificial
intelligence in industrial and medical fields.
Advanced economies are expected to expand by 1.8% in
2026. The United States is likely to lead this group with 2.4%
growth, supported by fiscal incentives and healthcare tax
reliefs from the One Big Beautiful Bill Act. This legislation
and the recovery from the late 2025 federal shutdown create
a strong framework for healthcare spending and private
investment. While the Eurozone faces slower growth at
1.3%, it remains a stable pillar of the global economy. Japan
is expected to grow by 0.7% under new fiscal policies.
Emerging markets remain a high-growth frontier with
momentum staying above 4.0%. China is expected to grow
by 4.5% due to domestic stimulus and more predictable trade
with the US. India remains a global leader with a 6.3% growth
rate and serves as a critical hub for manufacturing and digital
health innovation. Growth in the Middle East at 3.9% and in
Sub-Saharan Africa at 4.6% reflects regional stabilisation and
presents opportunities to reach more patients globally.
The financial environment is expected to improve as inflation
drops toward 3.4% by 2027. Lower price pressures and
interest rate cuts in the US and UK should make it easier
to fund large-scale research and development projects.
While global trade growth may slow to 2.6% because of
tariff adjustments, the technology and pharmaceutical
sectors remain strong to ensure the continued delivery of
essential medicines.
Indian Economy
The Indian economy exhibited resilience in FY26 amid
global trade uncertainties and market fluctuations. The
Second Advance Estimates indicate real GDP growth of
7.6% alongside Gross Value Added at 7.7%. These figures
underscore the strength of a domestic demand-led growth
trajectory. Robust agricultural performance bolstered rural
earnings. Urban consumption gained momentum from stable
jobs and easing inflation.
While early projections anticipated India overtaking Japan
to become the worlds fourth-largest economy, recent IMF
updates position India at the sixth spot. This adjustment is
primarily a reflection of currency fluctuations and statistical
baseline revisions rather than a deceleration in domestic
growth momentum. Current GDP stands at $4.15 trillion.
Projections position the country to claim third place by
2030 with a $7.3 trillion economy. This trajectory reaffirms
Indias status as the fastest-expanding major economy.
Domestic demand, durability and structural reforms provide
firm backing.
Private consumption continues as the key engine. Lower
inflation and rising real wages fuel this momentum. Public
capital expenditure reached 12.2 lakh crore. Such
outlays advanced infrastructure and stimulated sectors like
manufacturing, construction, and energy. Initiatives such
as Viksit Bharat 2047 advance self-reliance and capacity
enhancement despite external headwinds.
Average headline Consumer Price Index (CPI) inflation
recorded a historic low of 1.7% during the first nine months
of FY26, supporting domestic purchasing power through
sustained price stability. Due to the global distress, the
MoSPI finalised the inflation rate at 3.4% (as of March
2026), anchored by prudent government spending
and steady bank credit expansion. The banking sector
demonstrates resilience through robust capital buffers
and minimal non-performing assets, complemented
by foreign exchange reserves exceeding $ 700 billion
that fortify Indias capacity to navigate global volatility.
(Source: PIB, PIB 2, MoSPI )
Outlook
The outlook for the Indian economy stays positive and stable.
Projections place real GDP growth for FY27 between 6.8%
and 7.2%. These estimates highlight Indias ability to preserve
strong momentum despite worldwide uncertainties.
Government spending on infrastructure will continue to
provide solid support. Private sector investments keep
rising steadily. Policy measures and capacity building further
reinforce the manufacturing base. The services sector holds
its reliable growth path. Digital progress and resilient exports
lend additional strength. (Source: PIB)
Industry Overview
The Indian pharmaceutical industry is undergoing a structural
shift from a volume-based model to a value-driven innovation
leader. As of FY26, the sectors annual turnover reached
4.72 lakh crore, with the market projected to expand to
130 billion dollars by 2030. India continues to strengthen its
reputation as the "Pharmacy of the World" by meeting 20%
of the global generic drug demand and supplying 55-60%
of UNICEFs vaccine requirements, including 99% of WHOs
DPT demand. Domestic performance remains robust with
revenue growth projected at 8% to 10% for FY26, driven
by expansion into rural markets and the launch of chronic
therapy products. (Source: PB, Indian Century)
Government support is a primary catalyst for this growth
through significant fiscal allocations and policy reforms.
The Union Budget 2025-26 increased the funding for the
Department of Pharmaceuticals by 28.8% to 5,268 crore,
including specific outlays for bulk drug parks and medical
device clusters. Newer initiatives like the Biopharma Shakti
scheme, with a 10,000 crore outlay over five years, aim
to foster research in high-value areas such as biologics and
biosimilars. To improve operational efficiency, the government
is also working to resolve the inverted duty structure and
streamline GST refunds on input services, which will help
On the global front, Indian exports reached 30.4 billion dollars
in FY25 despite regulatory scrutiny and pricing pressures in
traditional markets like the United States. To mitigate these
risks, the industry is pivoting toward market diversification
in Europe, Africa, and Latin America. Strategic focus is
also shifting toward the Active Pharmaceutical Ingredient
(API) segment with a 60,000 crore push to reduce import
dependence. By integrating advanced technologies and
maintaining the highest number of USFDA-compliant plants
outside the US, the sector is well-positioned to lead the next
phase of global healthcare innovation. (Source: IBEF, PIB)
Company Overview
ZIM Laboratories Limited (ZIM or "the Company"),
founded in 1984, and commenced operations in 1989, is a
specialist firm focussed on the developing, manufacturing, and
global distribution of differentiated generic Pharmaceutical
and Nutraceutical products in oral solid dosage forms.
The Companys comprehensive services include both Pre-
Formulation Intermediates (PFI) and Finished Formulations
(FF) across numerous vital therapeutic areas globally.
ZIMs innovative drug delivery solutions and cutting-edge
technological platforms to boost patient convenience and
adherence to treatment significantly. With established
proficiency in producing complex and differentiated generic
products, ZIM utilises advanced delivery techniques and
varied release patterns to supply effective and readily
available healthcare solutions.
Key Therapy Areas and Dosage Offerings
The Companys core therapeutic focus areas include: Urology,
Gastrointestinal, NSAIDs / Analgesics, Anti-infectives,
Cardiovascular, Central Nervous System, and Vitamins
& Supplements.
Our wide range of dosage forms includes Tablets, Dry Syrups,
Directly Compressible (DC) Granules, Pellets, Capsules, Oral
Thin Films (OTF), and Taste-Masked Powders.
Manufacturing and Technology Capabilities
ZIMs advanced manufacturing process capabilities include:
Oral film casting, Stability enhancement, Transmucosal and
Multilayer film technologies, bi / multi-layer film casting, Active
nanoparticulate granulation, Solvent-less processing, Taste
masking, Solubility and Bioavailability enhancement, and
Multilayered pellets.
The Companys product differentiation is anchored by, unique
proprietary and non-infringing technology platforms:
- Micro-Emulsion Coating Technology (MECT)
- Pellet Cold Forming Technology (PCFT)
- Rapid Gelation Drug Release Technology (RGDRT)
- Matrix Pore Forming Tablet Technology (MAPOTAB)
ZIMs Innovative Products Basket, featuring New Innovative
Products (NIP) and Oral Thin Films (OTF), is strategically
positioned to achieve high-value revenue growth, expand
our global presence, and enhance patient outcomes.
The Company maintains a strong commitment to global
high-quality healthcare, continuously developing proprietary
technology and value-added generics through persistent
R&D efforts. ZIM acts as a key supplier of both finished and
semi-finished products within its targeted markets.
Advance Manufacturing Facility and Efficient R&D
Centre
ZIM operates three state-of-the-art manufacturing facilities
i.e. General, Cephalosporin, and OTF and a well-established
R&D centre, all staffed by highly skilled professionals.
These resources allow the Company to develop and
manufacture high-quality medicines that meet global
compliance requirements.
Key Certifications
The Companys commitment to quality and global standards
is demonstrated by its adherence to critical compliance
requirements, including:
- WHO-GMP (World Health Organisation Good
Manufacturing Practices)
- ISO 9001 (International Organisation for Standardisation)
- NSF/ANSI 455-2(NSF/American National Standards
Institute)
Global Presence and Operations
ZIM has established offices and subsidiaries in key locations,
including India, the UAE, Australia, and the EU. These strategic
hubs help the company run our global operations efficiently
and ensure we always comply with local regulations.
Additionally, ZIM has set up a Scientific Office (SO) in the
UAE. This office specifically manages the registration and
marketing of our innovative pharmaceutical and nutraceutical
products across the region.
The Companys integrated business model offers complete,
end-to-end product development solutions:
- Idea Generation: From initial product conceptualisation.
- Development & Filing: Through product development,
dossier development & filing.
- Approval & Supply: To secure Marketing Authorisation
(MA), manufacturing, and final supply.
Key Offerings
ZIMs product portfolio is built on value-added and
complex generic medicines offered through two main
forms: Pre-Formulation Intermediates (PFI) and Finished
Formulations (FF).
The Company develops these intermediates in close
collaboration with our distribution partners. This allows us to
deliver customised solutions for the development, sourcing,
and marketing of specific, differentiated generic products.
Further, our Finished Formulations include branded
generics. These are registered in select markets and
launched through partnerships with local distributors and
marketing companies.
Our innovative product basket has two core segments:
- New Innovative Products (NIP): This segment focusses
on advancing innovation. It includes complex generic
pharmaceuticals developed using our in-house
technology platforms. These next-generation complex
molecules are designed to become first- or second-
generation advanced generics in specific markets.
- Oral Thin Films (OTF): This line offers both branded
pharmaceutical and nutraceutical products delivered in
a patient-centric, innovative film format.
Performance Highlights
- Total Operating Income stood at 3,744 Mn,
impacted
by the geopolitical situation in the Middle East leading
to some loss of business.
- EBITDA declined by 16.4% YoY to 414 Mn. PAT
margin
declined by 160 bps to 1.6% in FY26, compared to 3.2%
in FY25.
- Export Revenue advanced 0.8% YoY to 3,150 Mn
from 3,125 Mn in FY25, sustained by consistent
demand from RoW and Pharmerging markets owing
to expansion of the team and hiring of a President of
International Business.
- NIP + OTF Sales Revenue aggregated 566 Mn,
representing 15% of Total Operating Revenue inclusive
of licensing fees, reinforcing the strategic importance of
our proprietary technology platforms.
- Research & Development Expenditure constituted
8.3% of Total Operating Income, reflecting our sustained
commitment to building a differentiated and future-
ready product pipeline.
- Finance Costs increased from 114 Mn to 132 Mn
in FY26, reflecting an increase in total borrowings
from 1,122 Mn to 1,230 Mn, deployed towards
plant and equipment upgrades in support of
infrastructure expansion.
- Dossier Licensing Income from NIP + OTF declined to
87 Mn in FY26 from 98 Mn in FY25, demonstrating
the growing commercial value and market receptivity of
our proprietary drug delivery technologies.
- Gross Block Additions during FY26 totalled 409 Mn,
of which 108 Mn was directed towards bioequivalence
studies and regulatory submissions in support of our
Developed Markets pipeline.
Export Business
The Company is continuously strengthening its global
footprint. We achieve this through strategic partnerships,
innovative R&D, and a growing local presence in key regions.
Our diverse technology and product portfolio allows us to
operate in 50+ countries, including:
- Key Emerging Regions: Asia (including India), Africa,
MENA (Middle East & North Africa), Latin America, and CIS.
- Developed and Pharmerging Markets: The EU,
Turkey, Canada, Australia, Saudi Arabia, and other high-
GDP markets.
To support this ongoing global expansion, ZIM is currently
reinforcing its Business Development team across all regions.
Domestic Business
The Company focusses on delivering unique, differentiated
Pharmaceutical and Nutraceutical products to a diverse
customer base. This includes central and state government
agencies, as well as private-sector pharmaceutical and
nutraceutical companies.
The Company strategically supplies high-margin, value-added
generic formulations under key government schemes. This
approach helps mitigate risks associated with price volatility
and delayed payments. Major initiatives we support include
Jan Aushadhi, CGHS (Central Government Health Scheme),
ESIC (Employees State Insurance Corporation), and the
Indian Railways.
ZIMs innovative formulations have gained strong traction
under these central and state government schemes. As a
result, domestic revenues contributed a substantial 16%
the Total Operating Income in FY26.
R&D - Driving Product Innovation
ZIM remains dedicated to developing differentiated
generics. The Company achieves this by leveraging
innovative, advanced drug delivery systems and proprietary
manufacturing technologies.
This commitment to innovation is backed by a powerful
R&D infrastructure. Our team consists of highly skilled &
focussed professionals, supported by continuous, long-term
investments in research and development.
- In FY26, 8.3% of total revenue was invested in R&D.
- Capital Expenses on BE-Study & Registration under R&D
amounted to 108 Mn during FY26, reflecting the Companys
continued commitment to expanding its product pipeline and
regulatory compliance
101 R&D Team size |
2 PHDs |
85 Post Graduate |
311Mn Allocation on Opex, Facility, BE Studies, Registrations, and for advancing the pipeline of innovative products |
3 NIP & 3 OTF EU Marketing Authorisations (MAs) received |
8 NIP filed in Europe (till date) |
Key filings and Business Updated
During FY26, ZIM completed a total of 57 regulatory filings
across key geographies, comprising 14 NIP filings, 29 OTF
filings, and 14 FF filings.
| Financial Performance | ||||
| Ratio | Year ended |
Year ended |
% change |
|
| Current ratio | Times |
1.45 |
1.39 |
4% |
| Debt- Equity Ratio | O/ % |
42% |
44% |
-7% |
| Debt Service Coverage Ratio | Times |
1.13 |
1.65 |
-32% |
| Return on Equity Ratio | O/ % |
2.13% |
5.38% |
-60% |
| Inventory Turnover Ratio | Times |
1.83 |
2.00 |
-8% |
| Trade Receivable Turnover Ratio | Times |
3.33 |
3.50 |
-5% |
| Trade Payable Turnover Ratio | Times |
4.00 |
4.42 |
-10% |
| Net Capital Turnover Ratio | ZE=2> Times |
4.38 |
5.84 |
-25% |
| Net Profit Ratio | O/ |
1.56% |
3.21% |
-51% |
| Return on Capital Employed | O/ % |
5.47% |
8.29% |
-34% |
| Operating Profit Margin | o/ |
5.72% |
7.76% |
-26% |
| Basic EPS | Times |
1.19 |
2.50 |
-52% |
| Interest coverage ratio | Times |
1.62 |
2.58 |
-37% |
(i) Debt Service Coverage Ratio: Decreased by 32% in the current year due
to decrease in profitability and increased finance costs and
borrowings
(ii) Return on Equity Ratio: Decreased by 60% in the current year due to decrease in profitability
(iii) Net Capital Turover Ratio : Decreased by 25% in the current year due to increased working capital
(iv) Net Profit Ratio: Decreased by 51% in the current year due to decrease in profitability and increased finance costs
(v) Return on Capital Employed: Decreased by 34% in the current year due to decrease in profitability
(vi) Operating Profit Margin: Decreased by 26% in the current year due to decrease in profitability
(vii) Basic EPS: Decreased by 52% in the current year due to decrease in profitability
(viii) Interest coverage ratio: Decreased by 37% in the current year is
mainly due to decrease in profitability and increased finance costs on
account of working capital utilisation
Strategic Way-forward
The Company aims to build on its established market
presence and expertise in drug delivery solutions to
unlock growth opportunities in both the Indian and global
pharmaceutical markets. With a strong commitment to
research and consistent delivery of differentiated products,
the Company is well-placed to drive business expansion in
the coming years. The Companys most important focus is
re-accreditation of plant with EU-GMP for which we have
invested in the CAPA plan successfully.
Re-accreditation of the manufacturing facility with EU-GMP
remains a top strategic priority. Having successfully invested
in and executed a comprehensive CAPA (Corrective and
Preventive Action) plan, the Company is positioned to reclaim
its operational foothold and accelerate growth in European
regulated markets.
Core Expansion Plan
- Portfolio Optimisation: ZIM aims to grow its key
segments, specifically the New Innovative Products (NIP)
and Oral Thin Films (OTF), by carefully optimising the
existing product portfolio.
- Market Targeting: The Company will direct its efforts
toward ROW and pharmerging, with an explicit focus on
returning to European regulated markets following EU-
GMP re-accreditation.
- Patient Focus: The Company remains dedicated to
extending product life cycles and prioritising patient
convenience through the application of innovative
technologies and differentiated product offerings.
- Value Delivery: ZIMs goal is to consistently deliver value-
driven products to partners and patients across both Rest
of the World (RoW) and Pharmerging markets.
In the coming years, ZIM is poised to advance through
strategic global collaborations, expanding its market reach
and generating synergies through key partnerships. The
recent approval to establish a subsidiary in Chile marks a
concrete step toward strengthening the Companys presence
in Latin America.
The Companys focus on R&D innovation will be strongly
reinforced by ongoing investments dedicated to:
- Bioequivalence studies
- Regulatory registrations
- Advanced drug delivery technologies
These initiatives are designed to support ZIMs deeper market
penetration into both regulated and emerging markets,
thereby ensuring sustained growth, product diversification,
and long-term success.
RISK MANAGEMENT
The Company encounter a range of risks stemming from both inherent
business characteristics and shifts in the external
landscape. Below, we identify some of these risks along with our proactive measures to
mitigate them:
| Risk | Impact |
Mitigation |
| Geo-Political and | Geopolitical instability, arising from shifts in |
- ZIMs extensive geographic presence, along with its diverse |
| Economic Risk | governments, policy changes, or
international |
product portfolio, significantly reduces
dependence on any |
| Registration and | The processes for obtaining regulatory |
- ZIM has implemented a proactive strategy for global market |
| manufacturing | approvals for both product registrations |
penetration. This approach includes launching a multi- |
| approval delays | and manufacturing involve extensive steps, |
country registration program, wherein
product dossiers are |
| Risk | Impact |
Mitigation |
| Competition Risk | The Indian Pharmaceutical
sector has a highly |
- ZIM strategically maintains a balanced
revenue contribution |
- The Companys long-term sustainability
is secured |
||
| Compliance & Regulatory Risk |
The Central Drugs Standard
Control |
- ZIM holds key certifications, including
NSF/ANSI 455-2, |
- Regular third-party audits and rigorous
compliance checks |
||
- The Company engages expert regulatory
consultants to |
||
| Cyber Security Threats & Data Protection Risk |
The Company faces a continually escalating |
- The Company utilises advanced
cybersecurity frameworks |
Opportunities and Challenges
Opportunities
- Global Generics Demand: The market for Indian generic
drugs continues its expansion, fuelled by the compelling
combination of cost-effectiveness and globally recognised
high-quality manufacturing standards.
- Strengthened Regulatory Landscape: The Indian
government has reinforced quality controls, notably
through the stricter enforcement of Good Manufacturing
Practices (GMP) under the revised Schedule M guidelines
(effective December 2023), combined with GST
rationalisation on essential medicines and increased risk-
based CDSCO inspections.
- China Plus One Advantage: Amidst geopolitical shifts,
global pharmaceutical companies are diversifying their
supply chains, positioning India as a significant growth
beneficiary for manufacturing, leveraging the "China Plus
One" strategy.
Challenges
- Counterfeit and Sub-standard Drugs: The pharmaceutical
industrys credibility is affected by the persistent issue
of counterfeit medication, particularly in developing
markets, eroding patient trust and posing risks to public
health. Maintaining strict quality systems, certifications,
and supply chain integrity is essential for reputable
manufacturers to differentiate themselves and protect
brand equity.
- Cybersecurity Exposure: The industry remains highly
vulnerable to cyber-attacks due to the presence of
extremely sensitive proprietary drug data and private
patient information.
- API Price Volatility: Currency fluctuations, inflation,
and policy changes directly impact the cost of Active
Pharmaceutical Ingredients (APIs), consequently exerting
pressure on profit margins.
- R&D Investment Pressure: Escalating costs associated
with research and development (R&D) place stress on
margins, demanding prudent and deliberate capital
allocation strategies.
IT Infrastructure and Technology
Enterprise Resource Planning (ERP)
The Companys ERP platform, Infionic, continued its phased
integration during FY26. The eLog (Electronic Logbook)
module is live and fully operational. Integration of LMS and
eDMS with Infionic is currently in progress.
Quality Management System (QMS)
Implementation of the Document Management System
(DMS) is in the rollout phase. e-BMR and TMS are planned for
subsequent phases. A dedicated QMS tool to manage Change
Control, CAPA, and Deviations is also planned, strengthening
compliance governance across manufacturing operations.
Human Resource Management System (HRMS)
The Companys HRMS platform, Keka, remains the backbone
of HR operations. Key modules Leave Management,
Attendance, Payroll, Helpdesk, and Recruitment are fully
operational, supporting an efficient and streamlined
process flow.
Cybersecurity and Data Protection
Sophos Firewall was upgraded during the year to enhance
network security. NIST certification is in progress. All
IT personnel were trained on updated IT SOPs and
security policies.
Way Forward
Following the successful deployment of eLog, ZIM will
prioritise LMS and eDMS implementation. A User Access
Management system is also planned to consolidate digital
governance and ensure secure, role-based access across
enterprise systems.
HUMAN RESOURCE
The Company significantly strengthened its Human Resources
function, placing a strong emphasis on diversity, inclusion, and
the well-being of its workforce. Demonstrating a commitment
to building a balanced staff, female representation reached
16.2%. At the leadership level, women account for 8.8% of
the 79 senior positions. The Company upholds a strict non-
discrimination policy broadened during the year to cover all
forms of discrimination and explicitly incorporating provisions
under the HIV and AIDS (Prevention and Control) Act, 2017,
and the Transgender Persons (Protection of Rights) Act,
2019. Ensuring all employees receive equal opportunities,
regardless of age, gender, ethnicity, or physical ability.
Furthermore, an HR Risk Management Subcommittee
continued to operate actively reviewing and ensuring fairness
and transparency in key decisions, such as disciplinary
actions, career advancement, and employee recognition.
Engagement, Development, and Safety
In line with its dedication to long-term employee welfare, the
Company continued to offer the National Pension Scheme
(NPS), thereby enhancing financial security and engagement.
HR policies continue to actively promote a performance-
driven and collaborative work environment, ensuring
employee interests align directly with organisational goals.
Workplace safety, remained a priority across all manufacturing
units. Enhanced protocols including the mandatory use of
Powered Air-Purifying Respirators (PAPRs) in designated
high-risk zones. The Internal Complaints Committee (ICC)
remained fully active in addressing concerns related to sexual
harassment, and the Company maintained a zero-complaint
record during the year.
Organisational Growth and Development
FY26 marked a defining chapter in ZIMs organisational
evolution, with strategic senior leadership additions including
the President of International Business, VP of Quality
Assurance, VP of Human Resources, and VP of Purchase
alongside meaningful strengthening across Regulatory
Affairs, Operations, and Projects & Engineering. The strategic
expansion of the technical team has also been crucial in
strengthening customer service capabilities and driving
overall efficiency. The Company actively fosters employee
engagement through various initiatives, including cultural
events, team-building activities, wellness programmes,
and employee recognition platforms, all designed to build
morale, support personal development, and promote
collaboration. By encouraging open communication and
cross-functional participation, the Company successfully
cultivates a strong sense of belonging and shared purpose.
As of 31st March, 2026, the Companys total workforce stood
at 632 employees, with 87 employees (14%) based outside
Maharashtra reflecting a dynamic team aligned with its long-
term vision.
Further to explore our commitment to employee development
and well-being, please refer to the Our Employees chapter
included in the ESG section within this Annual Report.
INTERNAL CONTROL SYSTEMS AND THEIR
ADEQUACY
Strong Internal Controls & Risk Management
Framework
The Company operates under a comprehensive internal
control system meticulously aligned with its operational scale,
complexity, and strategic objectives. This structure rests on
a foundation of robust risk management, financial discipline,
internal audit practices, and sound corporate governance.
The Company has implemented well-defined policies across
financial, operational, and compliance domains to ensure
overall efficiency and regulatory adherence. The framework
is specifically designed to provide reasonable assurance
regarding the following six key areas:
1. Adherence to all applicable laws and regulations.
2. Accuracy and completeness of financial and
accounting records.
3. Timely preparation of reliable financial reports.
4. Operational effectiveness and efficiency.
5. Safeguarding of assets against unauthorised access
or misuse.
6. Early detection and prevention of fraud and errors.
Proactive Risk Mitigation & Safety Enhancements
ZIM employs a preventive approach to safety and risk
management. This includes rolling out enhanced safety
protocols across all manufacturing units, including the
continued deployment of intrinsically safe Powered Air-
Purifying Respirators (PAPRs) in high-risk operational zones.
Both preventive and detective controls are actively maintained
to identify and address potential risks. A formally structured
Whistle-Blower Policy empowers directors, employees, and
stakeholders to report concerns confidentially. These reports
are formally reviewed by the Audit Committee and the Board
to ensure appropriate and timely action is taken.
Internal Audit Mechanism
Internal audits are executed through close coordination
between the Management and Internal Auditors. The scope
of these audits is extensive, including a thorough evaluation
of business processes, risk management practices, regulatory
compliance, and Internal Financial Controls (IFC), as stipulated
by the Companies Act, 2013. The Audit Committee and the
Board approve a structured internal audit plan annually,
which is executed quarterly. Key observations and action
items from previous audits are reviewed regularly to facilitate
continuous improvement. Management also engages in
frequent discussions with the Internal Auditors to implement
enhancements across all systems and processes.
Ongoing Evaluation & Governance
Acknowledging the inherent limitations of any internal
control system, ZIM maintains a dynamic and responsive
approach to control enhancements. The Audit Committee
and Risk Management Committee regularly assess audit
outcomes, recommend structural improvements, and
refine the Companys internal control environment. This
ensures strengthened operational resilience and effective
business continuity.
CAUTIONARY STATEMENT
This document contains forward-looking statements regarding
anticipated future events and the financial and operational
outcomes of ZIM Laboratories Limited. By their nature, such
statements require the Company to make certain assumptions
and are subject to inherent risks and uncertainties. There is
a material risk that the assumptions, predictions, and other
forward-looking statements contained herein may not prove
to be accurate. Readers are advised to exercise caution
and not place undue reliance on these forward-looking
statements, as various factors could lead to actual results
and events differing materially from those expressed.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
